We conducted a phase II study of docetaxel in combination with everolimus, a mammalian target of rapamycin (mTOR) inhibitor, for salvage therapy of advanced non–small-cell lung cancer (NSCLC) based on promising preclinical and early-phase clinical data. The combination of everolimus and docetaxel was tolerated well, but the efficacy was relatively modest in an unselected population of patients with NSCLC.
New study suggests the combination of targeting the MEK/ERK and PI3K/mTOR pathways has antitumor activity and could be a therapeutic option in the treatment of NRAS mutant melanoma, for which there are currently no effective therapies.
The combination pemetrexed–carboplatin could be a valuable treatment option in elderly patients, as indicated by this phase II trial. Neutropenia was the most common toxicity. The objective tumor response rate is within the range of data reported for pemetrexed–carboplatin in the general NSCLC population.